$Silo Pharma(SILO.US)$ NEWS Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention Silo Pharma announced promising results from a study on depression treatment and relapse prevention. This study, in collaboration with Columbia University, identified a new drug formulation that significantly improves mood stability without common side effects of current antidepressants. CEO Eric Weisblum emphasized the potential impact on millions suffering f...
$Silo Pharma(SILO.US)$ NEWS Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine Silo Pharma, a developmental stage biopharmaceutical company, will attend a hybrid public meeting hosted by the FDA and Reagan-Udall Foundation on June 27, 2024. The event, titled “Understanding Current Use of Ketamine for Emerging Areas of Therapeutic Interest,” will discuss ketamine's use for treating depression and chronic pain. CEO Eric Weisblum, along with a scientific a...
$Silo Pharma(SILO.US)$Well, FINTEL is now at zero shares LTB! Lets see if MM’s continue routing half the volume off exchange? Seems so far a lot is going to DP?? Grrrrr
$Silo Pharma(SILO.US)$ Feel bad for this stock with an important license for Alzheimer’s Disease. I hope you shorters don’t get DAT (Dementia of Alzheimer Type) disease in the future- or your family member. Believe me, you will regret this day.
Silo Pharma股票討論區
NEWS
Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention
Silo Pharma announced promising results from a study on depression treatment and relapse prevention. This study, in collaboration with Columbia University, identified a new drug formulation that significantly improves mood stability without common side effects of current antidepressants. CEO Eric Weisblum emphasized the potential impact on millions suffering f...
NEWS
Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine
Silo Pharma, a developmental stage biopharmaceutical company, will attend a hybrid public meeting hosted by the FDA and Reagan-Udall Foundation on June 27, 2024. The event, titled “Understanding Current Use of Ketamine for Emerging Areas of Therapeutic Interest,” will discuss ketamine's use for treating depression and chronic pain. CEO Eric Weisblum, along with a scientific a...
FYI
The global Alzheimer's disease therapeutics market size is forecasted to exceed $30.8 billion by 2033.
Feel bad for this stock with an important license for Alzheimer’s Disease. I hope you shorters don’t get DAT (Dementia of Alzheimer Type) disease in the future- or your family member. Believe me, you will regret this day.
暫無評論